Greenberg Bruce 的 Form 4/A 修正申報
修正Aldeyra Therapeutics, Inc.ALDX,2024/4/17 申報
- 申報編號
- 0000950170-24-045108
- 申報時間
- 2024/4/17
- 交易日
- 2024/3/11
- 申報延遲
- 37 天
- 10b5-1 計畫
- 沒有勾選
- 原始申報日
- 2024/3/12
這份申報列了 1 筆非衍生性交易。沿用原件裡沒有重述的 1 筆交易。公開市場賣出合計 $4.50 萬。交易後 37 天申報。
這份修正申報重述了 0000950170-24-030314(2024/3/12 申報)的一部分,沒有重述的交易仍然有效,列在下面。
申報人
一份 Form 4 可以有好幾位申報人,例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Greenberg BruceCIK 0001928391 | 高階主管(見申報備註) |
非衍生性證券(表 I)
普通股等股票的取得與處分,每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2024/3/11 | Common Stock | S賣出處分 | −13,201 | $3.41F2 | −$45,015.41 | 130,154 | 直接 |
沿用原件的交易
這份修正申報只重述了原件的一部分。原件其他的交易仍然有效,網站的交易表把它們算在這份修正申報底下。
來自 0000950170-24-030314(2024/3/12 申報)。
衍生性證券(表 II)
| 交易日 | 證券 | 交易 | 標的股數 | 單價 | 金額 | 交易後持有 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2024/3/9 | Common Stock | A公司授予取得 | +252,280 | $0.00 | $0 | 252,280 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報(Form 4/A)的全部附註,以及申報的備註。其他附註,例如間接持有的方式、交易計畫的細節,請看 SEC EDGAR 上的原文。
- F1
These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the settlement of certain time-based restricted stock unit awards. This sale was previously reported in the Reporting Person's Form 4 filed on March 12, 2024 (the "Original Form 4").
- F2
Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $3.27 to $3.58. The Reporting Person has provided to the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of shares sold at each separate price within the range.
表 I 有 1 筆交易的價格引用這則附註。
- F3
Adjusted to reflect 9,455 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan, which were inadvertently omitted in the Original Form 4. The amount in Column 5 of this Form 4 reflects the number of shares beneficially owned by the Reporting Person as of the date of this report after giving effect to the adjustment.
備註
Interim Chief Financial Officer